Recent research data surrounding this compound, specifically the high-dose formulation ZPHC ZPHC, suggest a significant impact on physique loss and associated chronic illnesses . Researchers posit that this dual agonist , affecting both GLP-1 and GIP receptors , may represent a major advance in the approach of overweight and related metabolic probl